Pharma BD Deal Intelligence

Servier / IDEAYA Biosciences, Inc.

2025 · Licensing/Option · $530M · Complete

Servier and IDEAYA Biosciences entered an exclusive license agreement for darovasertib, a potent and selective protein kinase C inhibitor in development for primary and metastatic uveal melanoma. Servier obtains regulatory and commercial rights in all territories outside the United States; IDEAYA retains US rights. IDEAYA receives $210 million upfront and is eligible for up to $320 million in milestones plus double-digit royalties on net sales. The parties collaborate on development and share associated costs.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Servier deals